Scientist Discover Protein Responsible for MPB - Huge News

Stem cell; cell based hair therapy
41

» » Well after reading this article for a second time, i am starting to be
» » cautious. It could also be an other attempt to sell un-proven topical
» cream
» » with nice biology-theory but no FDA results.
»
» I’m generally a bit cautious. This “breakthrough” might just well lead to
» nothing at all.

Yea, but it’s still worth contemplating and possibly trying to turn the oral pills into a topical when the pills come to market.

42

» I dont know if this means anything but
»
» ‘Niacin almost doubled plasma PGD2 and 5-HT, but aspirin reduced only PGD2
» by 86%. In contrast, luteolin inhibited both plasma PGD2 and 5-HT levels by
» 100 and 67%, respectively.’
»
» If you google luteolin and pgd2 it apparently strongly inhibits pgd2 in
» serum so is this worth taking?
»
» Also does this mean taking vitamin b supps with niacin is going to be bad
» for hair since it doubles pgd2.
»
» Just my own ponderings and not sure what it means.
»
» :expressionless:

It might just be a coincidence, but last year I took 500mg Niacin as a GH booster 5 days a week for about 6 months. In that time period, I went from a NW1 to a NW2 (I’m 20yo, was 19 when taking Niacin). Since I have stopped taking Niacin, I feel like my rate of loss has decreased. I am predisposed to MPB from my dad’s side (he was NW6 at 28) but safe from my mom’s side. This theory might definitely be legit, I can’t say for sure, but Niacin may have caused or accelerated my hair loss.

43

is that true?

Someone on another forum posted this about this new research,

Quote:
There are two types of PGD2 receptors, DP1 and DP2 (DP2 is also known as ‘GPR44’ and ‘CRTH2’). Laropiprant (Merck’s drug) selectively blocks the PD1 receptor - Cotsarelis showed that the PD2 receptor (and not PD1) is involved in hair growth downregulation. BTW, niacin produces flushing via the PD1 receptor - the PD2 receptor is not involved in the flushing at all.

and then this

Quote:
Setipiprant by Actelion blocks the right PGD2 receptor implicated in MPB (PD2). Right now, setipiprant is in phase 2/3 testing.

http://www.hairlosstalk.com/interact/viewtopic.php?f=32&t=72328

44

» is that true?
»
» Someone on another forum posted this about this new research,
»
» Quote:
» There are two types of PGD2 receptors, DP1 and DP2 (DP2 is also known as
» ‘GPR44’ and ‘CRTH2’). Laropiprant (Merck’s drug) selectively blocks the PD1
» receptor - Cotsarelis showed that the PD2 receptor (and not PD1) is
» involved in hair growth downregulation. BTW, niacin produces flushing via
» the PD1 receptor - the PD2 receptor is not involved in the flushing at
» all.
»
»
» and then this
»
» Quote:
» Setipiprant by Actelion blocks the right PGD2 receptor implicated in MPB
» (PD2). Right now, setipiprant is in phase 2/3 testing.
»
» http://www.hairlosstalk.com/interact/viewtopic.php?f=32&t=72328

That was posted by TAGOHL further up the page, someone has quoted him on another forum.

45

» Looking at the big picture for a moment -
»
» Any thoughts about whether this holds the possibility of restoring
» long-lost hair? Or are we looking at mainly a loss prevention method?
»
» Or do we not know enough to guess either way?

In this article about the findings Cotsarelis is quoted as saying

It’s also not known whether a treatment that inhibits PGD2 could restore hair to skin that’s already bald, Cotsarelis says, but he hopes that it might. In 2011, he and his team showed that hair-follicle stem cells are still intact in balding skin, but that their proliferation is inhibited5. If PGD2 is the inhibitor, then blocking it may allow stem cells to proliferate and give rise to new follicles. “Whether the follicle will be as big as before, it’s hard to know,” he says.

http://www.nature.com/news/clues-to-the-cause-of-male-pattern-baldness-1.10277

46

» hello everybody
»
» JUST ONE QUESTION…
»
» WHY WOMEN DON T HAVE MPB LIKE MEN IF THIS IS DUE TO THAT PROTEIN?
»
» sorry for killing your hope WITH THAT BASIC QUESTION BECAUSE DHT CAN
» EXPLAIN WHT WOMEN DONT HAVE MPB BUT THAT PROTEIN CAN’T
»
» SORRY FOR MY ENGLISH FROM FRANCE:-P

women do have androgenetic alopecia. there are 20 million women in america dealing with androgenetic alopecia. that is a lot of women.

47

» » Looking at the big picture for a moment -
» »
» » Any thoughts about whether this holds the possibility of restoring
» » long-lost hair? Or are we looking at mainly a loss prevention method?
» »
» » Or do we not know enough to guess either way?
»
» In this article about the findings Cotsarelis is quoted as saying
»
» It’s also not known whether a treatment that inhibits PGD2
» could restore hair to skin that’s already bald, Cotsarelis says, but he
» hopes that it might. In 2011, he and his team showed that hair-follicle
» stem cells are still intact in balding skin, but that their proliferation
» is inhibited5. If PGD2 is the inhibitor, then blocking it may allow stem
» cells to proliferate and give rise to new follicles. “Whether the follicle
» will be as big as before, it’s hard to know,” he says.
»
» Clues to the cause of male pattern baldness | Nature

well, of course as soon as the oral pill form of this stuff comes to market in a year or two we should make a topical version and try it.

48

So, what do we have in this story?
We know Merc’s laropiprant is targeting PGD1 protein receptors. So, it’s not what we want, unless you have flushing problem.
Actelion’s setipiprant indeed is targeting PGD2 protein receptor CRTH2 (Pulmonary Hypertension | Janssen).
But can someone confirm that CRTH2 is the same GPR44 receptor?
If that is true, soon we going to be able to buy this setipiprant from Switzerland, use it as tablets or crush it and make it as topical, and prove or dishonour Cotsarelis.

49

» Looking at the big picture for a moment -
»
» Any thoughts about whether this holds the possibility of restoring
» long-lost hair? Or are we looking at mainly a loss prevention method?
»
» Or do we not know enough to guess either way?

Theoretically, if you remove the inhibitor - the follicles should return to their normal state i.e. producing terminal hair. So, the study does imply that it will give us our hair back.

50

So, what do we have in this story?
We know Merc’s laropiprant is targeting PGD1 protein receptors. So, it’s not what we want, unless you have flushing problem.
Actelion’s setipiprant indeed is targeting PGD2 protein receptor CRTH2 (Pulmonary Hypertension | Janssen).
But can someone confirm that CRTH2 is the same GPR44 receptor?
If that is true, soon we going to be able to buy this setipiprant from Switzerland, use it as tablets or crush it and make it as topical, and prove or dishonour Cotsarelis.

51

» So, the study does imply
» that it will give us our hair back.

Of course - that’s one intention of Cots study.

On the other hand, it’s not so bad at least to imply this,
because this holds p…'s somewhat back from doing suicide or so.

52

» So, what do we have in this story?
» We know Merc’s laropiprant is targeting PGD1 protein receptors. So, it’s
» not what we want, unless you have flushing problem.
» Actelion’s setipiprant indeed is targeting PGD2 protein receptor CRTH2
» (Pulmonary Hypertension | Janssen).
» But can someone confirm that CRTH2 is the same GPR44 receptor?
» If that is true, soon we going to be able to buy this setipiprant from
» Switzerland, use it as tablets or crush it and make it as topical, and
» prove or dishonour Cotsarelis.

Yes. CRTH2 is GPR44. CRTH2 does play a role in mast cell-mediated immune responses such as those involved in allergic reactions

53

» So, what do we have in this story?

In fact, just another specific study - that’s all.

But what you guys completely IGNORE are all the other factors in this game:

Cotsarelis and his team are aware of it (study content/result/problem) since about 4-5 years - right?
Right - US20110021599A1 - Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph - Google Patents

So explain me - why the hell show all their NEW patents completely DIFFERENT approaches than blocking PGD2 or crap whatever??

Also, what they failed to explain is THE REASON (the cause) for higher PGD2 levels. So, what exactly causes higher levels of PGD2 in bald skin?

In other words, who or what exactly is responsible for the higher levels?

Blocking something, especially in this case, is just the attempt of moving around THE MAIN CAUSE!

54

» So, what do we have in this story?
» We know Merc’s laropiprant is targeting PGD1 protein receptors. So, it’s
» not what we want, unless you have flushing problem.
» Actelion’s setipiprant indeed is targeting PGD2 protein receptor CRTH2
» (Pulmonary Hypertension | Janssen).
» But can someone confirm that CRTH2 is the same GPR44 receptor?
» If that is true, soon we going to be able to buy this setipiprant from
» Switzerland, use it as tablets or crush it and make it as topical, and
» prove or dishonour Cotsarelis

Luteolin and Quercetin may help.
Ramatroban also but I dont know how safe is that.

55

No iron man. You’re totally unaware of how medical issues being addressed at this level. PGD2 protein on its own does no harm to hair. It’s only when it binds to specific receptor in this case GPR44, it starts to strangle follicle. Apart from that prostaglandins play key role in cell functions. You don’t wanna destroy elements that support your brain tissue, muscle regeneration and so on. Merc’s laropiprant also doesn’t block PGD1 protein but its specific receptors responsible for elevating flushing.
Interesting question would be – why do they bind to those receptors. But who cares, if you can disable them in any case.

56

i’m of the opinion that chasing down chemical pathways for baldness is a waste of time. Its a tangled up fishing line of proteins inter-connected with other proteins that in turn have an effect on some other protein or receptor. By the time its all mapped out, we’ll be in our graves.

Cotserellis is good at making headlines but not producing anything tangible as far as I can see.

57

There’s one thing here which I can’t get past. Somewhere in this thread (I think) was a post showing that this is actually an old discovery. So I am trying to figure out what aspect of this makes it news-worthy. Anyone ?

58

» There’s one thing here which I can’t get past. Somewhere in this thread (I
» think) was a post showing that this is actually an old discovery. So I am
» trying to figure out what aspect of this makes it news-worthy. Anyone ?

Because press is thinking Cotsarelis is the only hair scientist/reseacher on this planet?

J Ovarian Res. 2011 Feb 25;4:3.
Hematopoietic-Prostaglandin D2 synthase through PGD2 production is involved in the adult ovarian physiology.
Farhat A, Philibert P, Sultan C, Poulat F, Boizet-Bonhoure B.

Institut de Génétique Humaine, Department of Genetic and Development, CNRS UPR1142, 141, rue de la Cardonille, 34396 Montpellier CEDEX5, France. boizet@igh.cnrs.fr.

Abstract
BACKGROUND:
The prostaglandin D2 (PGD2) pathway is involved in numerous biological processes and while it has been identified as a partner of the embryonic sex determining male cascade, the roles it plays in ovarian function remain largely unknown. PGD2 is secreted by two prostaglandin D synthases (Pgds); the male-specific lipocalin (L)-Pgds and the hematopoietic (H)-Pgds.

METHODS:
To study the expression of the Pgds in the adult ovary, in situ hybridization were performed. Then, to evaluate the role of H-Pgds produced PGD2 in the ovarian physiology, adult female mice were treated with HQL-79, a specific inhibitor of H-Pgds enzymatic activity. The effects on expression of the gonadotrophin receptors FshR and LhR, steroidogenic genes Cyp11A1, StAR and on circulating progesterone and estradiol, were observed.

RESULTS:
We report the localization of H-Pgds mRNA in the granulosa cells from the primary to pre-ovulatory follicles. We provide evidence of the role of H-Pgds-produced PGD2 signaling in the FSH signaling through increased FshR and LhR receptor expression. This leads to the activation of steroidogenic Cyp11A1 and StAR gene expression leading to progesterone secretion, independently on other prostanoid-synthetizing mechanisms. We also identify a role whereby H-Pgds-produced PGD2 is involved in the regulation of follicular growth through inhibition of granulosa cell proliferation in the growing follicles.

CONCLUSIONS:
Together, these results show PGD2 signaling to interfere with FSH action within granulosa cells, thus identifying an important and unappreciated role for PGD2 signaling in modulating the balance of proliferation, differentiation and steroidogenic activity of granulosa cells.

→ Hematopoietic-Prostaglandin D2 synthase through PGD2 production is involved in the adult ovarian physiology | Journal of Ovarian Research | Full Text
<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<

59

Merck, based in Whitehouse Station, N.J., is testing laropiprant as a flushing inhibitor to be administered with niacin. Swiss-based Actelion’s setipiprant is being studied as a treatment for allergic inflammation of nasal pathways. Both therapies are in the final phase of testing generally needed for regulatory approval.

Merck isn’t studying the anti-flushing drug in hair loss, said Ian McConnell, a Merck spokesman. “We haven’t seen any signals” in patient trials that the therapy might reduce baldness, he said. Actelion isn’t testing setipiprant as a baldness treatment, said Roland Haefeli, a company spokesman.

So if they don’t even bother testing it … doesn’t it make it clear that it’s not gonna do anything ?

60

» So, what do we have in this story?
» We know Merc’s laropiprant is targeting PGD1 protein receptors. So, it’s
» not what we want, unless you have flushing problem.
» Actelion’s setipiprant indeed is targeting PGD2 protein receptor CRTH2
» (Pulmonary Hypertension | Janssen).
» But can someone confirm that CRTH2 is the same GPR44 receptor?
» If that is true, soon we going to be able to buy this setipiprant from
» Switzerland, use it as tablets or crush it and make it as topical, and
» prove or dishonour Cotsarelis.
take a look at this http://www.caymanchem.com/app/template/Product.vm/catalog/10006735

http://www.jimmunol.org/content/168/3/981.full.pdf